Vision Sciences will present at the next Morgan Stanley

MENLO PARK, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eye care technology company focused on creating innovative solutions to transform care and improve lives of Patients, today announced plans to attend the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Sight Sciences management is scheduled to participate in a fireside chat on Tuesday, September 13, 2022 at 7:20 a.m. ET. Interested parties can access a live and archived webcast of the Fireside Chat in the “Investors” section of the Company’s website at: https://investors.sightsciences.com/.

About vision science
Sight Sciences is an eye care technology company focused on developing and commercializing innovative solutions to transform care and improve the lives of patients. By using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that improve patient care and supplant outdated conventional approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye due to meibomian gland dysfunction (MGD), enabling in-office elimination of blockages of the glands by doctors to treat the root cause of dry eye. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise the trabecular meshwork.

For more information, visit www.sightsciences.com.

OMNI® and TearCare® are registered trademarks of Sight Sciences.
SION™ is a registered trademark of Sight Sciences.
© 2022 Vision Sciences. All rights reserved.

Investor contacts:
Philip Taylor
Gilmartin Group
415.937.5406
[email protected]

Comments are closed.